These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 21469915)
1. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. Carter JA; Joshi A; Kaura S; Botteman MF J Med Econ; 2011; 14(3):288-98. PubMed ID: 21469915 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom. Joshi AD; Carter JA; Botteman MF; Kaura S Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231 [TBL] [Abstract][Full Text] [Related]
5. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. Snedecor SJ; Carter JA; Kaura S; Botteman MF J Med Econ; 2013; 16(1):19-29. PubMed ID: 22870908 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. Reed SD; Radeva JI; Glendenning GA; Saad F; Schulman KA J Urol; 2004 Apr; 171(4):1537-42. PubMed ID: 15017215 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer. Snedecor SJ; Carter JA; Kaura S; Botteman MF Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308 [TBL] [Abstract][Full Text] [Related]
9. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610 [TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Carter JA; Joshi AD; Kaura S; Botteman MF Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254 [TBL] [Abstract][Full Text] [Related]
12. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. Cristino J; Finek J; Jandova P; Kolek M; Pásztor B; Giannopoulou C; Qian Y; Brezina T; Lothgren M J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692 [TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. McKeage K; Plosker GL Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018 [TBL] [Abstract][Full Text] [Related]
15. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. Henk HJ; Kaura S J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824 [TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Raje N; Roodman GD; Willenbacher W; Shimizu K; García-Sanz R; Terpos E; Kennedy L; Sabatelli L; Intorcia M; Hechmati G J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139 [TBL] [Abstract][Full Text] [Related]
18. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Saad F; Eastham J Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263 [TBL] [Abstract][Full Text] [Related]
19. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788 [TBL] [Abstract][Full Text] [Related]
20. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Saad F; Chen YM; Gleason DM; Chin J Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]